Roche

News

Swiss franc strength puts Roche's results in a poor light

Roche has started its financial reporting for 2026 with a 5% fall in first-quarter revenues, but says its underlying performance remains strong.

News

New data build case for Roche's oral BTK drug for MS

Roche remains confident in the prospects for its soon-to-be-filed oral BTK drug fenebrutinib for multiple sclerosis, despite safety concerns.

News

FDA kicks off review of Roche's Gazyva for wider lupus use

Roche could be just months away from an FDA approval of Gazyva as the first anti-CD20 therapy for systemic lupus erythematosus.

News

Roche places a $1bn bet on C4T degrader-antibody conjugates

Roche is paying $20 million upfront to secure rights to two degrader-antibody conjugates (DACs) for cancer developed by longtime partner C4T.

News

Alzheimer's biotech Korsana to go public via reverse merger

By merging with Cyclerion, Korsana will get a Nasdaq listing and additional cash to develop its new-generation amyloid-targeting drug for Alzheimer's.

News

One in four diabetics has undiagnosed heart failure; study

A study has found that undiagnosed heart failure can be detected in people with high-risk diabetes using a simple, GP-led care pathway.

Swiss franc strength puts Roche's results in a poor light

New data build case for Roche's oral BTK drug for MS

FDA kicks off review of Roche's Gazyva for wider lupus use

Roche places a $1bn bet on C4T degrader-antibody conjugates

Alzheimer's biotech Korsana to go public via reverse merger

One in four diabetics has undiagnosed heart failure; study

Parexel buys Vitrana to boost patient safety toolkit

Discover a new era of healthcare panel engagement: Grounded ...

Roche

Editor's Picks